Grand Rounds in Urology™ (GRU) publishes video presentations from world class thought leaders focu E. David Crawford, MD, serves as Medical Editor for GRU.
Grand Rounds in Urology™ (GRU) is a professional education organization with the mission of providing best practice and leading edge knowledge for the treatment of urologic disease. GRU has three primary educational functions:
Live Meetings: Organization and hosting of international conferences that bring together the top thought leaders in the treatment of urologic disease. GRU meetings focus on
Yahir Santiago-Lastra, MD, UC San Diego provides a clear framework for recognizing and managing pelvic organ prolapse in clinical practice.
Michael A. Liss, MD, PhD, MAS, MBA, FACS, UCSD Urology, presents updated approaches to screening that move beyond fixed PSA thresholds.
Dr. Mohit Khera, Baylor College of Medicine Department of Medicine, reviews controversies in , including indications, prostate cancer risk, and cardiovascular safety using TRAVERSE data.
Rana R. McKay, MD, FASCO, UC San Diego, and E. David Crawford, MD, highlight how prospective real-world evidence may help inform the use of relugolix as an oral ADT option.
Watch the full discussion below: https://grandroundsinurology.com/quality-of-life-adherence-and-adverse-events-among-patients-with-advanced-prostate-cancer-treated-with-relugolix-6-month-results-of-the-optyx-multicenter-registry/
Robert E. Reiter, MD, MBA, UCLA Health, provides a comprehensive overview of the current role and future potential of radioligand therapy in .
Helen L. Bernie, DO, MPH, Indiana University, reviews evidence for pe**le rehabilitation after and lessons learned from building a structured protocol.
E. David Crawford, MD and Scott B. Sellinger, MD, FACS, discuss CAPItello-281, patient selection, toxicity management, and precision medicine strategies.
Watch the full discussion below ⬇️:
https://grandroundsinurology.com/capitello-281-trial-pten-testing-and-treatment-in-metastatic-hormone-sensitive-prostate-cancer/
Daniel P. Petrylak, MD, Yale Cancer Center, reviews practical strategies for selecting between doublet and triplet therapy in metastatic hormone-sensitive prostate cancer ( ).
Helen L. Bernie, DO, MPH, Indiana University Department of Urology, reviews evidence on testosterone therapy and risk and management.
07/13/2026
Episode 13 of the GRUroCast is now streaming! 🎉
In this episode, Herbert Lepor, MD, shares his institution's long-term experience with for prostate cancer.
🎧 Listen now: https://open.spotify.com/episode/1Uw9ux2hX6DCAtn4mNuA92?si=l_u_AfRlSGOAKCebG1DKog